TABLE 4.
Microbiological outcomes at TOC visit by baseline pathogen in ME and MITT patient populations treated with linezolid or comparator drugsa
| Organism and patient population | % of patients cured (no. cured/total) after treatment with:
|
95% CI | P value | |
|---|---|---|---|---|
| Linezolid | Vancomycinb | |||
| MRSA | ||||
| ME | 88.6 (124/140) | 66.9 (97/145) | 12.38, 30.97 | <0.0001 |
| MITT | 71.0 (125/176) | 55.1 (102/185) | 6.08, 25.70 | 0.002 |
| MSSA | ||||
| ME | 84.9 (90/106) | 75.3 (70/93) | −1.47, 20.74 | 0.088 |
| MITT | 73.0 (92/126) | 66.4 (75/113) | −5.02, 18.30 | 0.264 |
| Streptococcus pyogenes | ||||
| ME | 86.7 (13/15) | 94.4 (17/18) | −27.97, 12.42 | 0.579 |
| MITT | 68.4 (13/19) | 65.4 (17/26) | −24.73, 30.81 | 0.915 |
a
TOC visits occured 7 days after the end of treatment. CI, confidence interval.
b
Patients could be switched to nafcillin, oxacillin, dicloxacillin, or flucloxacillin based on culture results.